Hyponatremia and antidiuresis syndrome

Hyponatraemia is a common electrolyte disorder with significant clinical consequences. While the role of antidiuretic hormone (ADH) in water balance is well established, recent evidence has highlighted complex interactions between water-electrolyte and carbohydrate metabolism. Prior research has shown that ADH is regulated by plasma osmolarity and non-osmotic factors like blood volume and stress. However, the distinction between various forms of hyponatraemia and their underlying pathophysiology remains unclear in some cases. Existing knowledge includes the classification of hyponatraemia based on volume status and osmolality. Yet, the specific mechanisms of inappropriate ADH secretion and its clinical implications remain underexplored. This gap motivated further investigation into the diagnostic criteria and treatment strategies for antidiuresis syndrome. The need for a more precise terminology and better understanding of clinical outcomes is evident.

This article aims to clarify the diagnostic and therapeutic aspects of antidiuresis syndrome, a condition characterized by inappropriate ADH secretion. The study focuses on distinguishing this syndrome from other forms of hyponatraemia and identifying its clinical implications. The motivation stems from the high morbidity and mortality associated with hyponatraemia, particularly in cases that appear asymptomatic. The authors propose a more accurate terminology than the traditional SIADH label. They also aim to highlight the importance of aetiological diagnosis based on plasma osmolality and blood volume assessment. The study addresses the need for improved diagnostic criteria and treatment strategies. It emphasizes the role of vasopressin in pathogenesis and the limitations of current therapeutic approaches. The ultimate goal is to enhance clinical understanding and management of this condition.

The study employs a review approach to synthesize existing literature on antidiuresis syndrome and hyponatraemia. It analyzes the role of ADH and its receptors in water balance regulation. The authors examine the clinical features of euvolaemic, hypoosmolar hyponatraemia. They compare the mechanisms of hypersecretion and undetectable vasopressin cases. The study reviews the diagnostic criteria based on plasma osmolality and blood volume assessment. It also considers the impact of hyperglycaemia and hypertriglyceridaemia on hyponatraemia classification. The authors assess the role of endocrinopathies in euvolaemic hyponatraemia. They evaluate the effectiveness of current treatment strategies and the limitations of available aquaretics.

The strongest finding is that antidiuresis syndrome occurs in 90% of cases due to vasopressin hypersecretion, with 10% having undetectable levels. The authors propose that the term 'antidiuresis syndrome' is more accurate than SIADH. Clinical symptoms of hyponatraemia are linked to severity, onset speed, and duration. Even moderate cases increase the risk of falls and rhabdomyolysis. Hyperglycaemia causes hyperosmolar hyponatraemia, while hypertriglyceridaemia leads to normoosmolar hyponatraemia. Hypovolaemic hyponatraemia is associated with gastrointestinal, renal, and cutaneous salt loss. Hypervolaemic hyponatraemia is seen in heart failure and nephrotic syndrome. The study also identifies familial and drug-induced causes of SIADH, including X-linked recessive mutations and interactions with antiretroviral drugs.

The authors synthesize evidence to support the use of 'antidiuresis syndrome' as a more precise term than SIADH. They emphasize the importance of distinguishing this syndrome from other forms of hyponatraemia. The clinical implications of hyponatraemia are closely tied to its severity and onset. The study highlights the risk of falls and rhabdomyolysis even in moderate cases. Diagnostic criteria should include plasma osmolality and blood volume assessment. The authors propose that treatment involves water restriction and demeclocycline. Aquaretics show clinical effectiveness but have not demonstrated mortality improvement. The study concludes that corticotropic and hypoaldosteronism deficits must be addressed in treatment.